Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

IMPORTANCE: Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. OBJECTIVE: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). DESIGN, SETTING...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Psychiatry
Auteurs principaux: Daly, Ella J., Singh, Jaskaran B., Fedgchin, Maggie, Cooper, Kimberly, Lim, Pilar, Shelton, Richard C., Thase, Michael E., Winokur, Andrew, Van Nueten, Luc, Manji, Husseini, Drevets, Wayne C.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2017
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838571/
https://ncbi.nlm.nih.gov/pubmed/29282469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamapsychiatry.2017.3739
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires